Tukysa

Seagen secures a speedy FDA review on Tukysa as Merck buyout talks reportedly stall
Seagen secures a speedy FDA review on Tukysa as Merck buyout talks reportedly stall
Endpoints
Seagen
Merck
M&A
Tukysa
Flag link:
Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe
Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe
Yahoo/Zacks.com
Seagen
Adcetris
Padcev
Tukysa
Tivdak
Merck
M&A
Flag link:
Seagen reports positive Phase II tucatinib data in colorectal cancer
Seagen reports positive Phase II tucatinib data in colorectal cancer
Clinical Trials Arena
Seagen
Tukysa
metastatic colorectal cancer
clinical trials
Flag link:
Seagen's potential breast cancer blockbuster Tukysa shows promise in colorectal cancer
Seagen's potential breast cancer blockbuster Tukysa shows promise in colorectal cancer
Fierce Pharma
Seagen
Tukysa
breast cancer
colorectal cancer
clinical trials
Flag link:
Seagen’s breast cancer drug Tukysa turned down by NICE
Seagen’s breast cancer drug Tukysa turned down by NICE
Pharmaforum
NICE
Seagen
breast cancer
Tukysa
Flag link:
Why Seattle Genetics Stock Jumped 24% in September
Why Seattle Genetics Stock Jumped 24% in September
Motley Fool
Seattle Genetics
Merck
oncology
Tukysa
Flag link:
Merck to acquire $1bn equity stake in Seattle Genetics; announces two oncology collaborations
Merck to acquire $1bn equity stake in Seattle Genetics; announces two oncology collaborations
Biopharma Reporter
Merck
Seattle Genetics
cancer
oncology
ADCs
Tukysa
ladiratuzumab vedotin
Flag link:
FDA approves first new drug under Project Orbis
FDA approves first new drug under Project Orbis
RAPS.org
FDA
Seattle Genetics
Tukysa
advanced HER2-positive breast cancer
breast cancer
Project Orbis
Flag link: